Orexo AB (publ.) today announces that the US Court of Appeals for the Federal Circuit found Orexo’s long term Zubsolv patent US 8,940,330 to be valid, and reversed the invalidity decision previously rendered by the District Court of Delaware in November 2016.
September 10, 2018
· 3 min read